凯发天生赢家一触即发首页

 Retroviral vector

Retroviral vector

Customized R&D is available to meet client needs, with research-grade retroviral vectors produced in 500 mL increments. The company provides comprehensive CDMO solutions, encompassing antibody screening, vector construction, viral vector packaging, CAR-T cell preparation, and in vitro/in vivo CAR-T cell activity validation. Furthermore, the company offers CAR-specific retroviral vector products targeting various tumor targets, such as BCMA, CD19, CD38, CD22, and EGFR/EGFRV III, all capable of efficiently transducing human primary T cells. The CD38 CAR, in particular, is a fully human anti-CD38 scFv structure obtained through phage display scFv antibody library screening, possessing independent intellectual property rights.
Description

Highlights

 The establishedstable cell linesfor retroviral vector transfectionretroviral vectors
. • The manufacturing process is further simplified.
Lower cost
 It allows for better control over product quality, giving it a significant advantage in later stages of industrialization.

Overview

Retroviruses , also known as retrotraceromycin , are a type of RNA virus whose genetic information is stored on RNA, not DNA. Unlike other RNA viruses, retroviral RNA does not self-replicate. After entering a host cell, the reverse transcriptase in the viral nucleus transcribes the RNA into cDNA, which is then used to synthesize double-stranded DNA. Integrase integrates this double-stranded DNA into the host cell's chromosomal DNA, thus introducing non-viral genes into the cell. These genes can then be transferred to daughter cells through mitosis in vitro. Retroviruses specifically infect dividing cells, such as embryonic stem cells, neural stem cells, hematopoietic stem cells, and blood cells. In practical applications, retroviral vectors are frequently used in cell and gene therapy due to their wide transfection range and high transfection rate. A

retroviral vector ( RVV ) is a viral expression vector designed based on the characteristics of retroviruses. By deleting some or all genes encoding viral particle structural proteins, and retaining only the cis-acting viral sequences necessary for viral packaging and transduction, more space is created for inserting foreign genes and partially inactivating the virus. This makes it easier to package large foreign gene fragments and improves safety. To generate infectious viral particles from non-replicating retroviral plasmids, the packaging cells used at Shenzhen Cell Valley provide viral structural proteins encoded by the gag, pol, and env genes. Only a single plasmid carrying the foreign gene needs to be transfected into the packaging cell line, and a stable retroviral cell line can be obtained through a two-step packaging method. By utilizing packaging cell lines expressing retroviral gag, pol capsid/reverse transcriptase, and env envelope proteins, pseudoviral particles with infectious capacity but no viral replication ability are generated. This stable retroviral cell line can produce retroviruses long-term with better batch-to-batch stability. Furthermore, the titer of retroviral vectors can be further improved through monoclonal selection , enabling industrial-scale production of retroviral vectors .
 

Examples of currently mass-producible carrier products


About Us
Scan to follow our latest newsScan to follow our latest news
Contact Us
400-800-1266

Working hours: Monday to Friday, 9:00-18:00

Contact:Ms. Lai

Email:laijiaqi@aicaocy.com

Address:No. 1, Rongtian Road, Jinsha Community, Kengzi Street, Pingshan District, Shenzhen, China (Hepure Biomedical Ecological Park)

Bottom Navigation
Shenzhen Cell Valley Biopharmaceutical Co., Ltd.​​ is a comprehensive one-stop outsourcing service provider in China focused on the cell and gene therapy industry. It is also one of the first CRO/CDMO companies in the country to possess GMP industrial production capabilities for clinical-grade retroviral vectors . The company is a major public technical service platform construction project for CRO/CDMO in Shenzhen and is included among the city's latest announced "20+8" strategic emerging industry projects.Shenzhen Cell Valley has the capability for standardized and industrialized production of GMP-grade cell products such as CAR-T cells. Its primary production lines include those for various cell products like CAR-T, CAR-NK, CAR-M, γδT, TIL, and TCR-T. Additionally, the company operates production lines for various viral vectors, including RVV, LVV, non-viral vectors, and AAV, as well as for cellular raw materials used in producing therapeutics such as exosomes, genetically engineered antibodies, cytokines, oncolytic viruses, and vaccines.
 Copyright 粤ICP备2024168379号 互联网药品信息服务资格证书:(粤)-非经营性-2022-0426  Technical Support:YouDian Software